CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced it has completed the sale of its BioReliance business unit to Avista Capital Partners for $210 million.
